News

Company News & Events

ORYZON appoints Manuel López-Figueroa of Bay City Capital to its Board of Directors

11 May 2020

MADRID, SPAIN and CAMBRIDGE MA.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with high unmet medical need, is pleased to announce the appointment of Dr. Manuel López-Figueroa of Bay City Capital as an independent director. Dr. López-Figueroa will be Lead Director and member of the Remuneration and Nomination Committee.

 

Click here to see the full Press Release

 

Posted In: 
News
Investors

Share this story